Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $83.2 million.

  • Abeona Therapeutics' Cash & Equivalents rose 418.07% to $83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.2 million, marking a year-over-year increase of 418.07%. This contributed to the annual value of $23.7 million for FY2024, which is 59.98% up from last year.
  • Per Abeona Therapeutics' latest filing, its Cash & Equivalents stood at $83.2 million for Q3 2025, which was down 49.22% from $163.9 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Cash & Equivalents registered a high of $163.9 million during Q2 2025, and its lowest value of $5.0 million during Q1 2023.
  • For the 3-year period, Abeona Therapeutics' Cash & Equivalents averaged around $41.4 million, with its median value being $17.9 million (2024).
  • As far as peak fluctuations go, Abeona Therapeutics' Cash & Equivalents soared by 431.29% in 2021, and later plummeted by 80.86% in 2023.
  • Abeona Therapeutics' Cash & Equivalents (Quarterly) stood at $38.8 million in 2021, then slumped by 62.52% to $14.6 million in 2022, then grew by 1.76% to $14.8 million in 2023, then surged by 59.98% to $23.7 million in 2024, then skyrocketed by 418.07% to $83.2 million in 2025.
  • Its last three reported values are $83.2 million in Q3 2025, $163.9 million for Q2 2025, and $84.5 million during Q1 2025.